Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma (NCT02441686), a na phase 2 study. The primary outcome is 4-Cycle Induction Overall Response Rate (ORR).

2. Clinical Question

3. Trial Design

This is a Phase II, single-group study of lenalidomide, subcutaneous bortezomib and dexamethasone in people with newly diagnosed multiple myeloma. The registry lists Dana-Farber Cancer Institute as sponsor and the study status as completed. Enrollment is recorded as 46. The allocation field is NA, and masking is listed as none. These details indicate that this was not a randomized, masked comparison between treatment groups.

The treatment description identifies an induction regimen of lenalidomide, subcutaneous bortezomib and dexamethasone. It gives the drug schedules during induction and states that stem cell mobilization occurs at the end of Cycle 4. Participants could elect to stop treatment at the end of Induction Cycle 4, although the registry description ends before completing that sentence. Stem cell mobilization and autologous stem cell transplant are also listed as interventions. Further treatment details, including a complete description of the transition from induction to subsequent treatment, are not reported in the registry record.

The primary endpoint concerns response during the first four cycles of induction. The stated follow-up timeframe for that outcome is up to 12 weeks. Secondary outcomes include median time to progression, the one-year progression-free survival probability, median duration of response and the one-year overall survival rate. The registry lists eight outcome measures overall, but does not report analysis results for the primary endpoint in the record.

Safety information is separated into induction and maintenance phase records. Those are treatment phases rather than randomized study arms. Their reported risk groups differ, and they should not be interpreted as independent comparison groups or as evidence of a treatment effect. The registry record does not report a separate control regimen against which to judge the response or safety findings.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Induction

Reasons for not completing this period:

Maintenance

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Evaluable for disease response analysis having started therapy and assessed for disease post-baseline.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: The analysis population is all enrolled participants.

6. Primary Endpoint

The registry lists the primary outcome as 4-Cycle Induction Overall Response Rate (ORR), measured over Participants were followed up to 12 weeks..

The primary endpoint is the 4-Cycle Induction Overall Response Rate. It is defined as the percentage of participants who achieved partial response or better during the first four cycles of induction, according to International Myeloma Working Group response criteria. The analysis population is described as participants who started therapy and had a post-baseline disease assessment. This definition focuses the measure on participants with an evaluable disease response rather than everyone enrolled.

Overall response rate is a binary-outcome summary: each participant in the analysis population either meets the response threshold or does not. The resulting percentage describes how frequently the defined response occurred in that population. In general, an early response endpoint can provide a direct summary of tumor response during a specified treatment period. It does not, by itself, describe how long a response lasts, whether disease later progresses, or how long participants live.

The endpoint specifies a 90% confidence interval as its dispersion measure. A confidence interval expresses uncertainty around an estimated percentage arising from sampling variability; a wider interval indicates less precision than a narrower one. The registry record does not report the observed response percentage, confidence interval limits, or the number of participants in the evaluable analysis population. The endpoint's result and its precision therefore cannot be assessed from the posted primary outcome information.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The study uses a single-group design. In general, a single-group study observes outcomes in participants receiving a specified regimen without assigning a concurrent control regimen for comparison. This design can describe outcomes and safety during treatment, but it does not provide the randomized contrast used to estimate how outcomes differ because of treatment. The registry lists allocation as NA, masking as none, and the model as single group; it does not report a randomized treatment comparison.

What does the response percentage represent?

The primary outcome is a binary response measure. For each participant in the defined analysis population, the response criterion is either met or not met. The percentage summarizes the share meeting the criterion. The criterion is partial response or better under International Myeloma Working Group criteria during the first four induction cycles. The stated analysis population includes participants who started therapy and had disease assessed after baseline. The registry does not give the count meeting the response criterion, the size of this analysis population, or the resulting percentage.

Restricting an analysis to participants with an assessable response can be reasonable when the endpoint requires a disease assessment. It also makes the analysis population important to interpretation. If participants without a post-baseline assessment differ systematically from those assessed, a percentage among evaluable participants might not represent outcomes among all enrolled participants. The reasons for non-evaluability, the number affected, and any methods for handling missing assessments are not reported in the registry record.

What does the confidence interval add?

A confidence interval conveys the uncertainty of an estimate due to sampling variation. In general, an interval around a response percentage gives a range of values compatible with the data under the method's assumptions. It is not a guarantee that the true value lies within a particular observed interval, and it does not address biases caused by study design or missing data. The registry names a 90% confidence interval for the primary endpoint, but does not report its limits or the method used to construct it. That method and the resulting degree of precision are therefore not available for assessment.

A percentage and its interval answer related but distinct questions. The percentage gives the estimated response frequency in the analysis population; the interval communicates statistical precision. A point estimate without its interval can leave substantial uncertainty about how stable the estimate is. Conversely, even a narrow interval in a single-group study would not create a randomized comparison or establish what would have happened under another treatment.

Why does the design affect interpretation?

Randomization is a general method for making treatment groups comparable with respect to measured and unmeasured participant characteristics, on average. This record does not describe randomization or a control group. Any response observed in this study would therefore be an outcome under the regimen, not a direct estimate of the difference between the regimen and an alternative. The treatment-phase records for induction and maintenance do not supply a control group: participants are not described as randomly assigned between those phases, and their risk sets differ.

Masking can reduce certain kinds of influence on treatment delivery or outcome assessment, depending on who is masked and how the outcome is measured. Masking is listed as none. The registry does not describe any alternative safeguards for response assessment, so those details should not be assumed. The response criteria are named, but the record does not explain who assessed disease or whether assessments were independently reviewed.

What can be said about sample-size planning?

The registry record does not report the trial's sample-size justification or a statistical plan for planning the enrollment. Any planning illustrations associated with posted results are not observed power and should not be presented as proof that the study could detect a particular effect. The stated general assumptions for such illustrations include a two-sided significance level of 0.05, equal allocation between two arms, a normal approximation, and an effect defined as a fraction of an observed effect. Those assumptions describe an illustration, not this trial's single-group design or its own documented design rationale. No numerical planning result is reported in the registry record.

For a binary outcome, the amount of information depends in part on the number of participants with an assessed outcome and the distribution of responses. A planned enrollment is not the same as an evaluable analysis population. The record's enrollment value does not reveal how many participants contributed to the primary endpoint. The absence of a reported response count and confidence interval prevents an independent check of the endpoint's precision.

Finally, the registry lists eight outcome measures and zero analyses. The outcome list signals that the study recorded more than the primary response question, but a listed measure is not the same as a reported result. Statistical methods for the secondary outcomes, including any adjustment for multiple testing or handling of censoring for time-to-event measures, are not reported in the registry record.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Lenalidomide, Subcutaneous Bortezomib, Dexamethaso")
n      <- c(40)
events <- c(38)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Lenalidomide, Subcutaneous Bortezomib, Dexamethaso  40  38  95.0  83.1  99.4  83.5  98.6  83.5  98.5

11. Multiplicity, Missing Data and Analysis Populations

The registry lists eight outcome measures, including the primary response endpoint and secondary progression, response-duration and survival outcomes. It records zero analyses. This means the outcome definitions are available, but the registry record does not provide analysis results for these measures. The statistical plan for selecting or prioritizing analyses is not reported.

When several outcomes are examined, the chance of a seemingly notable result can increase if each is assessed without accounting for the others. Statistical methods can address this issue through prespecified outcome hierarchies or adjustments, but the registry record does not report whether any multiplicity strategy was planned or used. It would be inappropriate to assume either that a correction was applied or that none was applied in a separate analysis.

The primary analysis population is defined as participants who started therapy and had a post-baseline disease assessment. That definition makes assessment availability part of inclusion in the endpoint analysis. The record does not report how many participants lacked an assessment, the reasons for missingness, whether missing outcomes were imputed, or whether sensitivity analyses were conducted. It also does not report a full analysis-set definition beyond the stated evaluable population.

These omissions limit interpretation of any response estimate that might appear elsewhere: the population contributing to the estimate and the handling of incomplete outcomes are key to understanding it. In this registry record, the primary result and evaluable count are also not reported, so their relationship to enrollment cannot be assessed.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: neutrophil count decreased (5.7%), upper respiratory infection (2.9%), colitis (2.9%), pneumonia (2.9%), sinusitis (2.9%).

The registry reports serious adverse event information separately for the induction and maintenance phases. During induction, 42 participants were listed as at risk, and 8 as affected by serious adverse events. During maintenance, 35 were listed as at risk, and 8 as affected. These are phase-specific records and should not be treated as randomized comparison groups. The registry also reports other adverse events for 42 of 42 participants in induction and 30 of 35 in maintenance. Deaths are reported as 0 in each phase record.

The listed serious adverse event terms include neutrophil count decreased at 5.7%, and upper respiratory infection, colitis, pneumonia, sinusitis and fall at 2.9% each. These are registry-listed percentages; the record does not provide further details about event timing, recurrence, severity grading beyond the serious-event classification, or attribution to treatment. A participant may experience more than one event, so the term-specific percentages should not be added or interpreted as a count of unique participants.

Adverse event reporting describes events observed in the study. Without a control group, it cannot establish whether an event was caused by the regimen or compare its frequency with another treatment.

13. What the Result Does, and Does Not, Mean

The record establishes that a completed Phase II, single-group study evaluated lenalidomide, subcutaneous bortezomib and dexamethasone in newly diagnosed multiple myeloma. It defines an early response endpoint based on partial response or better during the first four induction cycles, in participants who started treatment and had post-baseline disease assessment. It also identifies secondary outcomes and records adverse events by treatment phase.

What the record does not establish is the observed response rate. The primary response percentage, its 90% confidence interval and the evaluable analysis count are not reported in the registry record. As a result, readers cannot use this record to judge the estimated frequency of response or its precision. Secondary outcome results are not reported either. A completed status does not fill in those missing outcome estimates.

Even if the response estimate were available, the study's single-group design would limit causal interpretation. A response percentage among treated participants would describe what happened in that group; it would not quantify the difference between this regimen and an alternative. The study does not describe random allocation to a control group, and the induction and maintenance records are not like-for-like controls.

The safety information documents serious and other adverse events in the phase-specific risk groups and lists several serious event terms with percentages. Those observations can inform a description of events recorded during the study, but they do not by themselves establish causation or comparative safety. The record does not provide enough detail to resolve event attribution or all aspects of missing safety information.

Statistical interpretation also depends on who contributed data and how incomplete measurements were handled. The primary endpoint's evaluable-population definition is explicit, but its size and the approach to missing assessments are not reported. The record therefore supports a clear account of the trial structure and endpoint definition, but not a conclusion about the magnitude, precision or comparative meaning of the efficacy outcome.

14. Why This Trial Matters Statistically

This study illustrates why an endpoint definition and an endpoint result are not interchangeable. The registry gives a specific response criterion, assessment period and analysis-population definition, making clear what the primary measure was intended to capture. Yet without the observed percentage, confidence interval and evaluable count, the main statistical result cannot be assessed. Careful interpretation begins by distinguishing what was planned or defined from what was actually reported.

Its single-group structure is also important. A response percentage can describe outcomes among participants treated with the regimen, but a control group is needed for a direct randomized comparison. Recognizing that distinction prevents descriptive results from being read as causal evidence. It also explains why induction and maintenance records should not be compared as if participants had been assigned to alternative treatments.

The safety records provide a separate lesson in interpreting denominators and populations. Induction and maintenance have different reported risk groups, so figures should remain attached to their phase and denominator. Event-specific percentages describe listed terms, not necessarily a count of unique participants. Avoiding informal addition or phase-to-phase comparison preserves the meaning of the registry entries.

Finally, the record shows how missing statistical details constrain reproducibility. The evaluable-population definition is stated, while the count analyzed, missing-data approach, multiplicity strategy and statistical methods are not. Those gaps matter because they affect how precisely and broadly results can be interpreted. A transparent account of both reported results and unreported methods is essential when using registry data to understand a clinical study.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary result is absent from the registry record. Although the endpoint definition and its 90% confidence interval measure are specified, the response percentage, interval limits and evaluable-population size are not. This prevents assessment of both the magnitude and precision of the primary outcome.

The single-group design offers no randomized concurrent comparator. It can describe outcomes observed during the regimen but cannot separate treatment effects from other influences or directly estimate a difference from another regimen. The induction and maintenance safety records are phase-specific and should not be treated as comparative arms.

The analysis population requires participants to have started therapy and received a post-baseline disease assessment. The record does not say how many participants were excluded from response analysis, why assessments were unavailable, or how missing data were handled. The relationship between the enrollment of 46 and the primary endpoint population is therefore not reported.

Other important methods are also absent: the registry does not report the sample-size justification, the statistical analysis plan, the method used for the confidence interval, or any multiplicity strategy. It does not explain who assessed response or whether outcome assessments were independently reviewed. Secondary outcome definitions are listed, but their results are not reported in the registry record.

Safety interpretation is limited by the lack of a control group and by the phase-specific reporting. The listed event terms and percentages do not establish causality, and the record does not provide all details needed to assess event timing, recurrence, or attribution. These limits concern what can be concluded from the registry information, not necessarily what may have been assessed in study reports outside the registry record.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma — NCT02441686.
• Registry record last updated 2026-01-13; status last verified 2025-12.
• Results first posted 2024-03-04.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The registry describes a completed Phase II, single-group study of lenalidomide, subcutaneous bortezomib and dexamethasone for newly diagnosed multiple myeloma, with enrollment of 46. The primary endpoint is the percentage of evaluable participants achieving partial response or better during the first four induction cycles, using International Myeloma Working Group criteria. Its stated follow-up timeframe is up to 12 weeks.

The primary response estimate, its 90% confidence interval and the evaluable-population count are not reported in the registry record. Secondary outcomes include progression, response duration and survival measures, but their results are not reported. Safety entries are provided separately for induction and maintenance; they do not constitute randomized comparisons. The record supports interpretation of the study design and outcome definitions, but not a quantitative conclusion about primary efficacy or comparative treatment effects.